The perpetual motion machine

And How a Simple Constitutional Framework Could Break the Pattern

After dozens of conversations with pharmaceutical leaders across the globe, we uncovered an uncomfortable truth that everyone knows but rarely discusses openly.

Our industry has become a perpetual motion machine of strategic initiatives.

Not the kind that generates endless energy, but the kind that consumes it. It leaves organisations exhausted, frontline teams cynical, and genuine transformation perpetually out of reach.

The Pattern We Can't Escape

Picture this scenario, because you've likely lived it ↴

A new leader joins with a mandate for change. Previous initiatives, half-implemented and barely measured, are quietly shelved. New strategies, projects, technologies, and tactics are unveiled with enthusiasm and a ton of hope. PowerPoints cascade from global to regional to local teams. Project teams are set up. Agencies, tech firms, and consultancies are onboarded. Implementation begins.

Then, eighteen months later, before any meaningful results can be measured or learnings captured, that leader moves to the next role or another company.

A successor arrives. With their own vision, their own vendor relationships, their own "proven" methodologies.

Rinse. Repeat. The cycle begins again.

What's particularly striking is that after two or three of these cycles, the same initiatives often resurface!

Customer segmentation redux, omnichannel strategy 3.0, "this time it's different" digital transformation. You name it.

The institutional memory of what was tried, what worked, and what failed has evaporated with the departed leaders who championed these efforts in the first place.

The Hidden Cost of Motion Without Progress

This is more than just inefficiency. It's borderline organisational trauma.

Our conversations with frontline teams reveal a profound fatigue that goes beyond typical change resistance. We forget that these are the people who actually execute the strategies, who engage with HCPs, who make customer-centricity real or watch it remain theoretical. They've become masters at nodding through kick-off meetings while privately calculating how long this latest initiative will last.

The financial waste is staggering.

Millions spent on redundant projects, overlapping technologies, and contradictory consultancies.

But the human cost might be higher: talented teams who've learned that commitment is futile, that building for the long-term is naive, that the safest strategy is to wait it out.

Why This Happens

The drivers of this dysfunction are systemic, not personal:

1. Leadership tenure misalignment: The average pharmaceutical commercial leader stays in role for 2-3 years, but meaningful transformation takes 3-5 years to embed and show results. The incentive structure rewards launching initiatives, not completing them.

2. The innovation imperative: In an industry facing patent cliffs, pricing pressures, and digital disruption, standing still feels like falling behind. Every new leader needs to demonstrate they're driving change. Even when the organisation needs stability to digest previous changes.

3. Organisational amnesia: When leaders leave, they take their learnings with them. Without systematic knowledge capture, every successor starts from scratch, often repeating expensive experiments or abandoning promising work prematurely.

4. The shiny object syndrome: New technologies and methodologies emerge constantly: AI, omnichannel, personalisation engines, next-best-action algorithms. The pressure to adopt the latest innovation often overshadows the need to maximise existing investments.

A Radical Yet Simple Solution → The Constitution

What if pharmaceutical companies adopted something that sounds almost quaint in our age of disruption:

A constitution?

Yes, a constitution. Not a mission statement or a set of values, but a formal, board-approved framework of principles and methodologies that transcend individual leadership tenures. A living document that says: "These are the foundations we've proven work for our organisation, our customers, and our culture. They will not be abandoned without compelling evidence and organisational consensus."

What a Constitution Might Include:

Foundational Principles

• Our definition of customer-centricity and how we measure it

• The non-negotiable elements of our commercial model

• Our approach to data architecture and integration

• How we balance global consistency with local flexibility

Proven Methodologies

• Our validated customer segmentation framework

• The omnichannel orchestration model we've tested and refined

• Our approach to capability building and change management

• The KPIs that truly predict commercial success

Innovation Guardrails

• How we evaluate and integrate new technologies

• Minimum timeframes for initiative assessment before abandonment

• Requirements for documenting learnings before moving on

• Criteria for when constitutional principles can be amended

Continuity Mechanisms

• Mandatory handover processes capturing what worked and why

• Protected funding for multi-year initiatives

• Success metrics tied to long-term outcomes, not just launches

• Cross-functional governance that survives individual departures

The Objection We Anticipate (And Why It's Actually the Point)

"This would slow us down. We need agility, not bureaucracy."

Here's the counterintuitive truth: Real agility comes from stable foundations, not constant reconstruction. When you're not rebuilding your commercial infrastructure every two years, you can actually move faster on what matters: understanding changing customer needs, adopting relevant innovations, responding to market dynamics.

A constitution doesn't prevent change; it prevents arbitrary change. It forces the organisation to distinguish between genuine evolution based on evidence and change for change's sake.

From Perpetual Motion to Purposeful Progress

We recognise this idea might seem extreme, even naive. How could any pharmaceutical company with rotating leadership, quarterly pressures, and competitive dynamics commit to such stability?

But consider the alternative.

How many more cycles of reinvention can your organisation endure? How many more millions will be spent relearning the same lessons? How much more frontline cynicism can you afford?

The companies that will win in the next decade won't be those with the most initiatives, but those with the most disciplined execution of proven principles. They'll be the ones who've stopped mistaking motion for progress and built something worth sustaining.

A Challenge to Leaders

If you're a pharmaceutical leader reading this, we challenge you to ask three questions:

1. How many strategic initiatives from the past five years are still actively driving value in your organisation?

2. What percentage of your team's energy goes toward genuinely new value creation versus re-doing previous work?

3. If you had to write down the five commercial principles your organization has definitively proven work—principles worth preserving across leadership changes—could you?

The answers might be uncomfortable. But discomfort is the first step toward breaking the cycle.